Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04566614
Other study ID # CCR 5292
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date June 18, 2020
Est. completion date December 31, 2025

Study information

Verified date February 2023
Source Royal Marsden NHS Foundation Trust
Contact Naureen Starling, MBBS MRCP MD
Phone 0208664778
Email Naureen.Starling@rmh.nhs.uk
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The purpose of this study is to investigate the feasibility of using ctDNA to support cancer diagnosis and risk stratification where invasive aerosol generating testing (and/or tissue biopsy) is challenging due to infection risk, technical impracticalities and resource limitations, such as during the COVID-19 pandemic and the subsequent recovery period.


Description:

This is a prospective, single-centre cohort pilot study using ctDNA informed treatment decisions. If the pilot study is successful within certain tumour types then this protocol may be extended to investigate further the benefit of ctDNA informed treatment decision in those tumour types. Patients with suspected malignancy for whom invasive biopsy for definitive histological diagnosis is challenging either due to COVID-19-related resource limitations, infection control or technical feasibility will be considered for this study. In this setting liquid biopsy may be used in lieu of tissue biopsy to facilitate treatment or may be used to prioritise standard of care invasive diagnostic tests. The former includes patients who require repeat biopsies for genomic analysis following non-informative results where these would inform standard of care treatment (i.e. NICE (National Institute for Health and Care Excellence)/Cancer Drug Fund (CDF) approved drugs). Tumour types included in this study are therefore those where invasive aerosol generating diagnostic tests such as bronchoscopy, gastrointestinal endoscopy (including endoscopic ultrasound (EUS)) are part of the standard diagnostic pathway and where capacity for these tests has become severely constrained during (and likely after) the COVID-19 pandemic. Tumour types affected include some suspected biliary tract, bladder, colorectal, GIST, lung and pancreatic cancers. The study is planned to continue until a total of 144 patients have been enrolled. This is anticipated to take up to 12-18 months. Follow-up will continue until patients have diagnosis made (based on ctDNA result) and treatment decision made (deferred or immediate). Potential patients will be identified in and will usually at the multidisciplinary team (MDT) meeting. They will give consent to participate in the trial and offered a liquid biopsy (ctDNA) in lieu of a tissue biopsy if considered suitable for PREVAIL - ctDNA. This may include patients who require repeat biopsies for further genomic analyses when repeat biopsies are not feasible where liquid biopsy may support prioritisation for invasive diagnostics earlier. ctDNA analysis will involve copy number variant detection and low coverage whole genomic sequencing. ctDNA gene panels have already been validated against tissue based molecular diagnostics for paediatrics (ct_PAED) and colorectal cancer (ct_GI). This analysis will be performed in an accredited clinical diagnostic laboratory (Translational Research Laboratory, Institute of Cancer Research). Patients will be stratified for treatment or further investigation based on their ctDNA result (either positive or negative), suspected tumour type, radiological (including PREVAIL-imaging risk stratification pathway) and clinical characteristics. PREVAIL ctDNA- Part 2 Study: PREVAIL part 2 is a multi-centre, prospective study assessing the impact of Guardant360© liquid biopsy in patients with radiologically suspicious pancreatic cancer (PC) and biliary tract cancer (BTC)without histological confirmation of malignancy. Liquid biopsies will be implemented into the routine diagnostic pathway across 6 RMP sites for patients with radiologically suspicious stage III/IV PC/BTC as part of the ACCESS implementation programme. Over 12 months, approximately 650 patients will be identified at individual sites by the local team when seen for an invasive procedure and referred in parallel to the Guardant360© test. These patients will proceed through an invasive diagnostic pathway as is standard of care and have a liquid biopsy as a new standard of care. Most patients will undergo both invasive tissue biopsy and liquid biopsy. Patients with informative liquid biopsy result, but without a histological diagnosis of cancer (either due to inconclusive biopsy result or if the invasive procedure hasn't been performed) will be considered suitable for the study. Only patients with detectable ctDNA without histological confirmation will be suitable for this study (approximately ¼ of patients entering the ACCESS programme). The study is planned to run parallel to the ACCESS implementation programme and it aims to enrole 150 patients. As part of this study, treatment may be recommended based on the liquid biopsy result. Patients with an invasive biopsy result which is suitable to guide treatment will not be eligible. ctDNA results will be discussed at the molecular tumour board (MTB) to provide clinical context and validity of the genomic result. In addition, all patients will be discussed at a central upper gastrointestinal cancer multidisciplinary team meeting (MDM) to discuss treatment based on ctDNA results. Treating clinicians will have access to the MTB outcome and patients may be treated based on the ctDNA result in the context of symptoms, tumour markers, and imaging results as a complete diagnostic package.


Recruitment information / eligibility

Status Recruiting
Enrollment 294
Est. completion date December 31, 2025
Est. primary completion date July 31, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Participants aged =18 years old - Patients with suspected malignancies of early stage colorectal cancer (FIT intermediate and high risk), early and late stage pancreatic cancer, biliary tract cancer, gastro-intestinal stromal tumours, lung cancer or bladder cancer, without a definitive histological diagnosis (including those with inconclusive biopsy result) or - Patients with histological diagnosis of lung cancer without adequate tissue for NHS genomic test directory predictive biomarker testing - Ability to provide informed consent. - Patients with performance status suitable for oncological treatments (ECOG performance status 0-2). Exclusion criterion: • Patients with an established histological diagnosis adequate to support standard of care treatment PART 2: Inclusion criteria - Included in the ACCESS implementation programme - Has detectable ctDNA on Guardant360© assay - Discussion at molecular tumour board and central multi-disciplinary meeting confirming ctDNA variant is supportive of diagnosis of PC/BTC (diagnostic or consistent with) - Performance status suitable for oncological treatment - Ability to provide informed consent Exclusion criteria 1. Previously diagnosed invasive or haematological malignancy within the past 3 years 2. Outcome at the molecular tumour board not supportive of cancer diagnosis (possibly consistent or not consistent)

Study Design


Intervention

Other:
ctDNA blood sampling
Screening/baseline blood sample to be analysed for ctDNA

Locations

Country Name City State
United Kingdom Royal Marsden Hospital Sutton Surrey

Sponsors (1)

Lead Sponsor Collaborator
Royal Marsden NHS Foundation Trust

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary ctDNA detection rate within different cancer types (and overall) The primary endpoint, ctDNA detection rate, overall and within different cancer types will be presented as a proportion of patients with a positive ctDNA test out of those tested, with 90% confidence intervals Throughout study completion, up to one year
Primary PREVAIL ctDNA Part 2 Study Primary end point, Proportion of patients with detectable ctDNA which supports a diagnosis of malignancy and commence treatment To run parallel for 12 months alongside the ACCESS implementation programme
Secondary Proportion of patients with a positive ctDNA result which identified a diagnosis and/or commenced treatment All secondary endpoints will be analysed in the patients diagnosed with suspected cancer, i.e. positive ctDNA result, unless stated. They will also be presented overall and by cancer type. The proportion of patients with positive ctDNA result which identified a diagnosis and/or commenced treatment will be presented as a proportion with 90% confidence intervals Throughout study completion, up to one year
Secondary Proportion of patients with a positive ctDNA result which assisted in prioritising invasive diagnostic tests Proportion of patients with positive ctDNA result which assisted in prioritising invasive diagnostic tests will be presented as a proportion with 90% confidence intervals Throughout study completion, up to one year
Secondary The association of ctDNA result (positive versus negative) and the PREVAIL-imaging pathway scoring result The association between ctDNA result (positive versus negative) and the PREVAIL-imaging pathway scoring result will be assessed descriptively by presenting cross-tabulations and relevant proportions Throughout study completion, up to one year
Secondary Estimation of the cost of liquid biopsy in lieu of tissue biopsy as compared to standard of care investigations and treatments prioritisation Simple estimation of the cost of liquid biopsy in lieu of tissue biopsy as compared to standard of care investigations and treatments prioritisation will be performed Throughout study completion, up to one year
Secondary PREVAIL ctDNA Part 2 Study secondary end point 1a Treatment response objective response rate To run parallel for 12 months alongside the ACCESS implementation programme
Secondary PREVAIL ctDNA Part 2 Study secondary end point 1b Progression free survival To run parallel for 12 months alongside the ACCESS implementation programme
Secondary PREVAIL ctDNA Part 2 Study secondary end point 1c Overall survival To run parallel for 12 months alongside the ACCESS implementation programme
Secondary PREVAIL ctDNA Part 2 Study secondary end point 2 Proportion of patients who undergo a repeated invasive procedure To run parallel for 12 months alongside the ACCESS implementation programme
Secondary PREVAIL ctDNA Part 2 Study secondary end point 3a- comparison with NHS targets Comparison of diagnostic pathway duration with NHS faster Diagnostic Standard (FDS) To run parallel for 12 months alongside the ACCESS implementation programme
Secondary PREVAIL ctDNA Part 2 Study secondary end point 3b- comparison with NHS targets Comparison of diagnostic pathway duration with 62 day wait target To run parallel for 12 months alongside the ACCESS implementation programme
Secondary PREVAIL ctDNA Part 2 Study secondary end point 4a Type of complications from invasive diagnostic procedures To run parallel for 12 months alongside the ACCESS implementation programme
Secondary PREVAIL ctDNA Part 2 Study secondary end point 4b Frequency of complications from invasive diagnostic procedures To run parallel for 12 months alongside the ACCESS implementation programme
Secondary PREVAIL ctDNA Part 2 Study secondary end point 4c Severity of complications from invasive diagnostic procedures To run parallel for 12 months alongside the ACCESS implementation programme
Secondary PREVAIL ctDNA Part 2 Study secondary end point 5 Number and type of invasive procedures performed To run parallel for 12 months alongside the ACCESS implementation programme
Secondary PREVAIL ctDNA Part 2 Study secondary end point 5b Number of histopathology reviews To run parallel for 12 months alongside the ACCESS implementation programme
Secondary PREVAIL ctDNA Part 2 Study secondary end point 5c Number of tissue based NGS performed To run parallel for 12 months alongside the ACCESS implementation programme
Secondary PREVAIL ctDNA Part 2 Study secondary end point 6a Healthcare costs associated with diagnostic pathway To run parallel for 12 months alongside the ACCESS implementation programme
Secondary PREVAIL ctDNA Part 2 Study secondary end point 6b Cost per-quality adjusted-life-year of diagnostic pathway To run parallel for 12 months alongside the ACCESS implementation programme
Secondary PREVAIL ctDNA Part 2 Study secondary end point 6c Number of hospital visits in diagnostic pathway To run parallel for 12 months alongside the ACCESS implementation programme
Secondary PREVAIL ctDNA Part 2 Study secondary end point 6d Length of hospital stay during diagnostic pathway To run parallel for 12 months alongside the ACCESS implementation programme
See also
  Status Clinical Trial Phase
Recruiting NCT01950572 - Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
Completed NCT03101566 - Study of Nivolumab in Combination With Gemcitabine/Cisplatin or Ipilimumab for Patients With Advanced Unresectable Biliary Tract Cancer Phase 2
Recruiting NCT05237193 - A Prospective Study of UCAD for Diagnosing Benign or Malignant Biliary Obstruction and Follow-up
Not yet recruiting NCT06037655 - Chemotherapy Combined With Adebrelimab and Mecapegfilgrastim in Neoadjuvant Treatment of Potentially Resectable BTC Phase 2
Recruiting NCT04584008 - Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics N/A
Completed NCT00196105 - Malignant Obstruction ZILVER Against Routine Therapy (MOZART I) N/A
Completed NCT02558959 - Second-line Irinotecan and Capecitabine Versus Irinotecan for Gemcitabine and Cisplatin Refractory Biliary Tract Cancer Phase 2
Completed NCT02829918 - Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers Phase 2
Completed NCT02784353 - Clinical Outcomes of Preoperative and Postoperative Rehabilitation in the Patients With HBP Malignancy N/A
Recruiting NCT05429203 - Comparison of Duodenoscope With Single-use Distal Cover and the Conventional Reusable Duodenoscope N/A
Recruiting NCT02255669 - Fully Covered SEMS Versus Partially Covered SEMS With Anti-migration System for Malignant Distal Biliary Obstruction N/A
Completed NCT01731821 - Nonstented Stump-closed vs Duct-to-Mucosa Pancreaticojejunostomy After Pancreaticoduodenectomy Phase 3
Completed NCT00422409 - Endoscopic Stenting of Gastrointestinal Cancer N/A
Terminated NCT02900248 - CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice
Recruiting NCT03063554 - EUS BD vs ERCP TP for Pancreatic Cancer N/A
Terminated NCT02615210 - Mid-Atlantic Research Group Single-Operator Cholangioscopic Assessment of Biliary Strictures N/A
Completed NCT04595058 - LAMS Choledochoduodenostomies: With or Without Coaxial Plastic Stent N/A
Recruiting NCT04856761 - A Study of Capecitabine Versus S-1 as Adjuvant Therapy in Patients With Biliary Tract Carcinoma After Surgical Resection
Recruiting NCT03427242 - Apatinib for Advanced Biliary Carcinoma Phase 2
Recruiting NCT05615818 - Personalized Medicine for Advanced Biliary Cancer Patients Phase 3